Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Cervical Cancer

Free Subscription Articles published in Eur J Cancer Retrieve available abstracts of 12 articles: HTML format

Single Articles

May 2025
1. WANG H, Wang N
   Letter Re: Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial.
   Eur J Cancer. 2025 May 19:115515. doi: 10.1016/j.ejca.2025.115515.
   PubMed    
   
   
   April 2025
2. ONAL C, Elmali A, Demirhan B, Guler OC, et al
   Letter comments on: "Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial".
   Eur J Cancer. 2025 Apr 22:115448. doi: 10.1016/j.ejca.2025.115448.
   PubMed    
   
   
   
3. EMINOWICZ G, Vaja S, Hackshaw A, McCormack M, et al
   Response to letter Re: Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial.
   Eur J Cancer. 2025 Apr 22:115449. doi: 10.1016/j.ejca.2025.115449.
   PubMed    
   
   
   March 2025
4. EMINOWICZ G, Vaja S, Gallardo D, Kent C, et al
   Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial.
   Eur J Cancer. 2025;220:115375.
   PubMed     Abstract available
   
   
   February 2025
5. HASEGAWA K, Nishio S, Yamamoto K, Fujiwara H, et al
   Tegafur-uracil maintenance chemotherapy post-chemoradiotherapy for cervical cancer: Randomized trial.
   Eur J Cancer. 2025;219:115304.
   PubMed     Abstract available
   
   
   January 2025
6. OAKNIN A, Monk BJ, de Melo AC, Kim HS, et al
   Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial.
   Eur J Cancer. 2025;216:115146.
   PubMed     Abstract available
   
   
   October 2024
7. WENZEL HHB, Schnack TH, Van der Aa MA, Jensen PT, et al
   Risk factors for lymph node metastasis in women with FIGO 2018 IA cervical cancer with a horizontal spread of > 7 mm.
   Eur J Cancer. 2024;212:115063.
   PubMed     Abstract available
   
   
   September 2024
8. BIZZARRI N, Querleu D, Ramirez PT, Dostalek L, et al
   Survival associated with the use of sentinel lymph node in addition to lymphadenectomy in early-stage cervical cancer treated with surgery alone: A sub-analysis of the Surveillance in Cervical CANcer (SCCAN) collaborative study.
   Eur J Cancer. 2024;211:114310.
   PubMed     Abstract available
   
   
   March 2024
9. TUNINETTI V, Virano E, Salutari V, Ricotti A, et al
   Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study.
   Eur J Cancer. 2024;203:114039.
   PubMed     Abstract available
   
   
   February 2024
10. TANAKA LF, Schoffer O, Schriefer D, Schauberger G, et al
    An audit of 1632 routinely collected cervical cancer screening smears from 398 women in Germany: Results from the TeQaZ Study.
    Eur J Cancer. 2024;201:113915.
    PubMed     Abstract available
    
    
    August 2023
11. DING S, Li H
    Re: A federated approach to identify women with early-stage cervical cancer at low risk of lymph node metastases.
    Eur J Cancer. 2023 Aug 1:112978. doi: 10.1016/j.ejca.2023.112978.
    PubMed    
    
    
    February 2023
12. WENZEL HHB, Hardie AN, Moncada-Torres A, Hogdall CK, et al
    A federated approach to identify women with early-stage cervical cancer at low risk of lymph node metastases.
    Eur J Cancer. 2023;185:61-68.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Cervical Cancer is free of charge.